TD Waterhouse Canada’s Protalix BioTherapeutics PLX Stock Holding History

TD Waterhouse Canada’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Hold	6,000	–	–	﹤0.01%	1749
2026 Q1	$13K	Hold	6,000	–	–	﹤0.01%	1697
2025 Q4	$10.7K	Hold	6,000	–	–	﹤0.01%	1528
2025 Q3	$14K	Hold	6,000	–	–	﹤0.01%	1470
2025 Q2	$8.76K	Hold	6,000	–	–	﹤0.01%	1485
2025 Q1	$15.2K	Hold	6,000	–	–	﹤0.01%	1317
2024 Q4	$11.1K	Hold	6,000	–	–	﹤0.01%	1388
2024 Q3	$6.24K	Hold	6,000	–	–	﹤0.01%	1442
2024 Q2	$6.84K	Hold	6,000	–	–	﹤0.01%	1424
2024 Q1	$7.44K	Hold	6,000	–	–	﹤0.01%	1431
2023 Q4	$10.4K	Hold	6,000	–	–	﹤0.01%	1244
2023 Q3	$9.42K	Hold	6,000	–	–	﹤0.01%	1244
2023 Q2	$10.9K	Hold	6,000	–	–	﹤0.01%	1227
2023 Q1	$13.2K	Hold	6,000	–	–	﹤0.01%	1165
2022 Q4	$8.16K	Hold	6,000	–	–	﹤0.01%	1250
2022 Q3	$6.3K	Hold	6,000	–	–	﹤0.01%	1314
2022 Q2	$6.48K	Hold	6,000	–	–	﹤0.01%	1333
2022 Q1	$6.24K	Hold	6,000	–	–	﹤0.01%	1419
2021 Q4	$5.76K	Buy	+6,000	New	+$6.28K	﹤0.01%	1432

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

TD Waterhouse Canada's PLX Position: Q2 2026 in Review

TD Waterhouse Canada held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 6,000 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

TD Waterhouse Canada first reported a position in PLX in Q4 2021 and has held it in 19 quarters since. The position peaked at $15.2K in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

TD Waterhouse Canada held 6,000 shares of Protalix BioTherapeutics worth $13.8K as of Q2 2026.
TD Waterhouse Canada left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1749 holding.
TD Waterhouse Canada first reported a position in Protalix BioTherapeutics in Q4 2021 and has held it in 19 quarters since.
TD Waterhouse Canada's Protalix BioTherapeutics position peaked at $15.2K in Q1 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.